{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006206","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.101101+00:00","generated_at":"2026-06-10T01:35:41.719088+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Arbutus announces multiple abstracts accepted for AASLD 2023, including late-breaking imdusiran data","bullets":["Late-breaking poster on imdusiran (AB-729) followed by VTP-300 or placebo in chronic hepatitis B subjects.","Poster #1459-C shows baseline HBV SNPs do not impact HBsAg reductions from imdusiran.","Oral presentation on 48-week vebicorvir + imdusiran + NrtI combination in eAg-negative CHB (Nov 12).","Preclinical data on oral small-molecule liver-tropic PD-L1 inhibitor for HCC (Nov 13)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006206","json":"https://secwatch.observer/filing/0001171843-23-006206.json","markdown":"https://secwatch.observer/filing/0001171843-23-006206.md","text":"https://secwatch.observer/filing/0001171843-23-006206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006206/0001171843-23-006206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006206/f8k_101123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:35:41.719088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}